Home > Services > Clinical Research Studies > Clinical Trials Details
<< Back to Results
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Contact Phone: 218-786-3308 | 1-844-681-7944
Locations: Essentia Health Cancer Centers
For more information about a financial conflict of interest (FCOI) or to review the Essentia Health FCOI policy, click here.